Global Plasmid Market was Valued at US$ 89.52 million in 2018 and is Estimated to Reach US$ 447.68 Million by 2027, growing at a CAGR of 19.5% over the Forecast Period, Owing to Growing Awareness about Gene Therapy, says Absolute Markets Insights
A plasmid is a small, circular piece of deoxyribonucleic acid (DNA), which is all the genetic material found in an organism’s chromosomes and replicates independently of chromosomal DNA. Worldwide rising awareness levels about gene therapy across the globe in recent years is fostering the market growth. According to an article published by Human Gene Therapy, the adoption of gene therapy for chronic diseases, which include Alzheimer Disease is high around the world as compared to less severe diseases, namely, attention deficit hyperactivity disorder (ADHD). Gene therapy is a promising treatment option for various diseases such as inherited disorders, some types of cancer, and certain viral infections; and most commonly, gene therapy is an approach to treat the genetic disorders. Rising number of clinical trials related to gene therapy coupled with increasing funding for research and development activities is likely to nourish the global plasmid market during the forecast period. Surging waves of advanced genetic information have marked the advent of gene therapy revolution in the recent decade. The profound knowledge about gene therapy has accelerated the potential of human genetics and disease, therefore paving the way for gene therapy in pharmaceuticals in the 21st century.
Major participants in the global plasmid market are adopting growth strategies such as new product launches, mergers and acquisitions, collaborations, partnerships, geographical and operational expansions, among others in order to gain a competitive advantage. For instance, in July 2019, Mirus Bio LLC launched TransIT-VirusGEN SELECT Transfection Reagent, which was designed for the drug discovery pipeline in gene and cell therapy manufacturing process.
The detailed research study provides qualitative and quantitative analysis of global plasmid market. The market has been analyzed from demand as well as supply side perspective. The demand side analysis covers market revenue across regions and further across all the major countries. The supply side analysis covers the major market players and their regional and global presence and strategies. The geographical analysis emphasizes on each of the major countries across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Purchase the complete report titled “Global Plasmid Market - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2015-2027” at
https://www.absolutemarketsinsights.com/reports/Plasmid-Market-2019-2027-363
Global Plasmid Market Share, by Region, 2018 (%)
Key Findings of the Report:
- In terms of revenue, the global plasmid market is expected to reach US$ 447.68 Mn by 2027
- On the basis of general type plasmid, non-conjugative segment will follow the conjugative segment over next nine years as non-conjugative plasmids are incapable of initiating conjugation and they can only be transferred through sexual conjugation with the assistance of conjugative plasmids
- By specific plasmid types, the F-plasmids segment dominated the market in 2018 as F-plasmids can be inserted into chromosomal DNA and are termed episomes. F plasmids enable the genetic exchange of material among cells and control sexual functions of bacteria with a fertility inhibition systems.
- Based on application, the gene therapy segment accounted for the highest market share in 2018 and is expected to continue its supremacy throughout the forecast period as there has been a considerable growth in gene therapy research in terms of volume, investments, and outcomes over a recent few years
- Europe represented the second largest plasmid market in 2018 due to high demand for innovative therapies for chronic diseases and rising prevalence of cancer among all age groups in the region. In addition, highly developed healthcare infrastructure primarily in Germany, Switzerland, the UK, and France is expected to drive the regional market growth.
- Some of the players operating in the global plasmid market are Aldevron, GenScript, PlasmidFactory GmbH & Co. KG, VGXI, Inc., Oxford Genetics Ltd., Applied StemCell, Altogen Biosystems, Cobra Biologics, Copernicus Therapeutics, Inc., Takara Bio Inc., InvivoGen, Miltenyi Biotec, MaxCyte, Inc., Mirus Bio LLC, MolMed S.p.A., GenePharma Co., Ltd., Polyplus Transfection, and other market participants
Global Plasmid Market:
- By General Type Plasmid
- Conjugative
- Non-Conjugative
- By Specific Plasmid Types
- F-Plasmids
- Resistance Plasmids
- Virulence Plasmids
- Degradative Plasmids
- Col Plasmids
- Cryptic Plasmids
- By Application
- Transfection
- Gene Therapy
- Recombinant DNA Technology
- Others
- By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxemburg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East and Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
